Glaukos Corporation (GKOS) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-23

What protects it: the moat

It protects its market position through its status as the first mover in MIGS and proprietary platforms like the iDose TR drug delivery implant.

The company relies on FDA clearances and first-of-its-kind designations to prevent competition from eroding its pricing power in the glaucoma and corneal disorder markets.

Its iStent products are reinforced by established reimbursement from Medicare and major private payers, while newer products like Epioxa provide an incision-free alternative to traditional surgery, creating a barrier for competitors limited to standard invasive procedures.

What could damage it

Prolonged U.S. government shutdowns could permanently impair earnings by halting FDA regulatory reviews and disrupting Medicare reimbursement for its medical procedures.

Because the company is reliant on federal regulatory oversight and government-funded medical payments, a freeze in federal staffing or funding targets its core commercialization mechanism.

If the FDA cannot timely process submissions or health care providers cannot secure reimbursement, hospitals may cease purchasing iStent and iDose TR products, causing a breakdown in the company's financial liquidity.

About Glaukos Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Other companies in Medical Devices